习惯性使用氨基葡萄糖与脓毒症风险:一项16年随访研究
该研究基于U.K. Biobank前瞻性收集数据的回顾性队列,纳入437,133名参与者,通过基线触摸屏问卷收集氨基葡萄糖使用信息。中位随访13.6年期间,发生13,458例脓毒症和2,555例脓毒症后28天内死亡。多变量调整模型显示,习惯性使用氨基葡萄糖与脓毒症风险较低(HR 0.87;95%CI 0.83-0.92)及脓毒症后28天死亡率较低(HR 0.79;95%CI 0.70-0.89)相关,分层和敏感性分析结果一致。中介分析显示,1.2-7.0%的脓毒症关联和2.8-5.4%的28天死亡率关联通过炎症生物标志物(包括C反应蛋白和系统性免疫炎症指数)介导(所有p<0.001)。
要点
- 在437,133名U.K. Biobank参与者中,习惯性使用氨基葡萄糖与脓毒症风险较低相关(HR 0.87;95%CI 0.83-0.92)。
- 习惯性使用氨基葡萄糖与脓毒症后28天死亡率较低相关(HR 0.79;95%CI 0.70-0.89)。
- 中位随访13.6年,共发生13,458例脓毒症和2,555例脓毒症后28天内死亡。
- 1.2-7.0%的脓毒症关联和2.8-5.4%的28天死亡率关联由炎症生物标志物(包括C反应蛋白和系统性免疫炎症指数)介导(所有p<0.001)。
- 分层和敏感性分析中上述关联一致。
适用人群与场景
- U.K. Biobank中437,133名参与者,基线通过触摸屏问卷收集氨基葡萄糖使用信息。
研究设计与关键结果
- 研究类型:基于前瞻性收集数据的回顾性队列研究;样本量437,133名U.K. Biobank参与者;中位随访13.6年。
- 主要终点:脓毒症发生风险,习惯性使用氨基葡萄糖组HR 0.87(95%CI 0.83-0.92)。
- 关键次要终点:脓毒症后28天死亡率,习惯性使用氨基葡萄糖组HR 0.79(95%CI 0.70-0.89)。
- 随访期间共13,458例脓毒症和2,555例脓毒症后28天内死亡。
- 中介分析:1.2-7.0%的脓毒症关联和2.8-5.4%的28天死亡率关联通过炎症生物标志物(包括C反应蛋白和系统性免疫炎症指数)介导(所有p<0.001)。
- 分层和敏感性分析结果一致。
证据类型、等级与局限
- 证据类型:回顾性队列研究(基于U.K. Biobank前瞻性收集数据)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐;原文结论为习惯性使用氨基葡萄糖与脓毒症风险及脓毒症后死亡率较低相关,观察到的关联可能部分通过炎症通路介导。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Despite the well-documented anti-inflammatory and antioxidant properties of glucosamine, a supplement commonly used to relieve osteoarthritis and joint pain, its potential link with sepsis is yet to be elucidated. To evaluate the association between habitual glucosamine use and the risk of sepsis and 28-day mortality following sepsis in a large cohort.
DESIGN: A large-scale cohort study.
SETTING: This was a retrospective cohort study of prospectively collected data, including 437,133 participants of the U.K. Biobank.
PATIENTS: A total of 437,133 participants from the U.K. Biobank.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Information on glucosamine use was collected through touchscreen questionnaires at baseline. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for the associations between habitual glucosamine use and risk of sepsis and 28-day mortality following sepsis. During a median follow-up of 13.6 years, 13,458 incident cases of sepsis and 2,555 deaths within 28 days post-sepsis were identified. In the multivariable-adjusted model, habitual glucosamine use was associated with a lower risk of sepsis (HR, 0.87; 95% CI, 0.83-0.92) and 28-day mortality following sepsis (HR, 0.79; 95% CI, 0.70-0.89). These associations were consistent across stratified and sensitivity analyses. Mediation analysis revealed that 1.2-7.0% of the association for sepsis and 2.8-5.4% of the association for 28-day mortality following sepsis were mediated through inflammatory biomarkers, including C-reactive protein and systemic immune-inflammation index (all p < 0.001).
CONCLUSIONS: Our findings elucidated that habitual use of glucosamine was associated with lower risks of sepsis and post-sepsis mortality. The observed associations might be partially mediated through inflammatory pathways.
参考来源
- Xu S, Kong X, Shi J, et al. Habitual Glucosamine Use and Risk of Sepsis: A 16-Year Follow-Up Study. Crit Care Med. 2025. PMID: 40504933. doi:10.1097/CCM.0000000000006742
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。